newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2Phase 3 HI AVANT (avexitide) Program: Startup Activities